ACE2: more of Ang-(1–7) or less Ang II?
- 1 January 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Nephrology and Hypertension
- Vol. 20 (1), 1-6
- https://doi.org/10.1097/mnh.0b013e3283406f57
Abstract
Purpose of review Previous concepts regarding the pathways involved in the generation of angiotensin II (Ang II) have been challenged by studies showing the existence of a peptide acting as an endogenous antagonist of Ang II. The discovery that angiotensin-(1–7) [Ang-(1–7)] opposes the pressor, proliferative, profibrotic, and prothrombotic actions mediated by Ang II has contributed to the realization that the renin–angiotensin system is composed of two opposing arms: the pressor arm constituted by the enzyme angiotensin-converting enzyme (ACE), Ang II as the product, and the Ang II type 1 (AT1) receptor as the main protein mediating the biological actions of Ang II; the second arm is composed of the monocarboxypeptidase angiotensin-converting enzyme 2 (ACE2), Ang-(1–7) produced through hydrolysis of Ang II, and the Mas receptor as the protein conveying the vasodilator, antiproliferative, antifibrotic, and antithrombotic effects of Ang-(1–7). Recent findings Experimental and clinical studies demonstrate a role for the Ang-(1–7)/ACE2/Mas axis in the evolution of hypertension, the regulation of renal function, and the progression of renal disease including diabetic nephropathy. Additional evidence suggests that a reduction in the expression and activity of this vasodepressor component may be a critical factor in mediating the progression of cardiovascular disease. Summary Further research on the contribution of the Ang-(1–7)/ACE2/Mas axis to cardiovascular pathology will lead to the development of new pharmacological approaches resulting in the design of molecular or genetic means to increase the expression of ACE2, allow for increased tissue levels of Ang-(1–7), or both.Keywords
This publication has 78 references indexed in Scilit:
- Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- The Antithrombotic Effect of Angiotensin-(1-7) Involves Mas-Mediated NO Release from PlateletsMolecular Medicine, 2008
- Increased Expression of Angiotensin Converting Enzyme 2 in Conjunction with Reduction of Neointima by Angiotensin II Type 1 Receptor BlockadeHypertension Research, 2008
- ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1–7)Kidney International, 2006
- G-Protein–Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 ReceptorCirculation, 2005
- Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy manJournal Of Hypertension, 2005
- Comparative studies of vasodilating effects of angiotensin-(1-7) on the different vessels.2004
- Synergistic effect of angiotensin-(1–7) on bradykinin arteriolar dilation in vivoPeptides, 1999
- Expression of the mouse and rat mas proto‐oncogene in the brain and peripheral tissuesFEBS Letters, 1995
- Release of nitric oxide by angiotensin‐(1–7) from porcine coronary endothelium: implications for a novel angiotensin receptorBritish Journal of Pharmacology, 1994